Nwam LLC Sells 2,997 Shares of Natera, Inc. $NTRA

Posted by on Jul 16th, 2026

Nwam LLC trimmed its holdings in Natera, Inc. (NASDAQ:NTRA – Free Report) by 31.0% in the 1st quarter, Holdings Channel reports. The fund owned 6,681 shares of the medical research company’s stock after selling 2,997 shares during the quarter. Nwam LLC’s holdings in Natera were worth $1,336,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of NTRA. Integrated Wealth Concepts LLC boosted its holdings in Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth raised its position in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after buying an additional 474 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Natera during the second quarter valued at about $298,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Natera in the second quarter valued at about $558,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

NASDAQ:NTRA opened at $277.37 on Thursday. The company has a 50-day moving average of $231.43 and a 200-day moving average of $219.80. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The company has a market capitalization of $39.72 billion, a price-to-earnings ratio of -170.17 and a beta of 1.51.

Analyst Ratings Changes

A number of research firms recently weighed in on NTRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. JPMorgan Chase & Co. upped their price target on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Barclays reduced their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Wednesday, June 24th. Wolfe Research started coverage on Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective on the stock. Finally, Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Check Out Our Latest Research Report on NTRA

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 3,405 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the completion of the transaction, the insider owned 142,295 shares in the company, valued at $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the sale, the director directly owned 1,076,198 shares in the company, valued at $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 178,872 shares of company stock valued at $39,627,696. Corporate insiders own 5.05% of the company’s stock.

Natera Company Profile

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Featured Stories

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.